These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 37572326)

  • 1. Molecular modeling strategy for detailing the primary mechanism of action of copanlisib to PI3K: combined ligand-based and target-based approach.
    Zhu J; Li X; Meng H; Jia L; Xu L; Cai Y; Chen Y; Jin J; Yu L; Gao M
    J Biomol Struct Dyn; 2024 Sep; 42(15):8172-8183. PubMed ID: 37572326
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Copanlisib: Novel PI3K Inhibitor for the Treatment of Lymphoma.
    Kumar A; Bhatia R; Chawla P; Anghore D; Saini V; Rawal RK
    Anticancer Agents Med Chem; 2020; 20(10):1158-1172. PubMed ID: 32183683
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Copanlisib for treatment of B-cell malignancies: the development of a PI3K inhibitor with considerable differences to idelalisib.
    Krause G; Hassenrück F; Hallek M
    Drug Des Devel Ther; 2018; 12():2577-2590. PubMed ID: 30174412
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery and SAR of Novel 2,3-Dihydroimidazo[1,2-c]quinazoline PI3K Inhibitors: Identification of Copanlisib (BAY 80-6946).
    Scott WJ; Hentemann MF; Rowley RB; Bull CO; Jenkins S; Bullion AM; Johnson J; Redman A; Robbins AH; Esler W; Fracasso RP; Garrison T; Hamilton M; Michels M; Wood JE; Wilkie DP; Xiao H; Levy J; Stasik E; Liu N; Schaefer M; Brands M; Lefranc J
    ChemMedChem; 2016 Jul; 11(14):1517-30. PubMed ID: 27310202
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In silico discovery of potent and selective Janus kinase 3 (JAK3) inhibitors through 3D-QSAR, covalent docking, ADMET analysis, molecular dynamics simulations, and binding free energy of pyrazolopyrimidine derivatives.
    Faris A; Hadni H; Ibrahim IM; Elhallaoui M
    J Biomol Struct Dyn; 2024 Jun; 42(9):4817-4833. PubMed ID: 37338041
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 3D-QSAR, Virtual Screening, Docking and Design of Dual PI3K/mTOR Inhibitors with Enhanced Antiproliferative Activity.
    Oluić J; Nikolic K; Vucicevic J; Gagic Z; Filipic S; Agbaba D
    Comb Chem High Throughput Screen; 2017 Aug; 20(4):292-303. PubMed ID: 28460621
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High-throughput virtual screening of phenylpyrimidine derivatives as selective JAK3 antagonists using computational methods.
    Faris A; Ibrahim IM; Hadni H; Elhallaoui M
    J Biomol Struct Dyn; 2024 Sep; 42(14):7574-7599. PubMed ID: 37539779
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of Copanlisib in Combination with Eribulin in Triple-negative Breast Cancer Patient-derived Xenograft Models.
    Guo Z; Luo J; Mashl RJ; Hoog J; Maiti P; Fettig N; Davies SR; Aft R; Held JM; Govindan R; Ding L; Li S; von Morze C; Wulf GM; Shoghi KI; Ma CX
    Cancer Res Commun; 2024 Jun; 4(6):1430-1440. PubMed ID: 38717161
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quantum biochemistry description of PI3Kα enzyme bound to selective inhibitors.
    Freitas de Sousa FJ; Nunes Azevedo FF; Santos de Oliveira FL; Vieira Carletti J; Freire VN; Zanatta G
    J Biomol Struct Dyn; 2024 Nov; 42(18):9283-9293. PubMed ID: 37632299
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular docking and MD simulation studies of 4-thiazol-N-(pyridin-2-yl)pyrimidin-2-amine derivatives as novel inhibitors targeted to CDK2/4/6.
    Liang JD; Zhang YE; Qin F; Chen WN; Jiang WM; Fang Z; Liang XL; Zhang Q; Li J
    J Cancer Res Clin Oncol; 2024 Jun; 150(6):302. PubMed ID: 38856753
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rational Design of Novel Phosphoinositide 3-Kinase Gamma (PI3Kγ) Selective Inhibitors: A Computational Investigation Integrating 3D-QSAR, Molecular Docking and Molecular Dynamics Simulation.
    Li K; Zhu J; Xu L; Jin J
    Chem Biodivers; 2019 Jul; 16(7):e1900105. PubMed ID: 31111650
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Copanlisib: An Intravenous Phosphatidylinositol 3-Kinase (PI3K) Inhibitor for the Treatment of Relapsed Follicular Lymphoma.
    Eltantawy A; Vallejos X; Sebea E; Evans K
    Ann Pharmacother; 2019 Sep; 53(9):954-958. PubMed ID: 30813760
    [No Abstract]   [Full Text] [Related]  

  • 13. Preclinical Activity of PI3K Inhibitor Copanlisib in Gastrointestinal Stromal Tumor.
    García-Valverde A; Rosell J; Serna G; Valverde C; Carles J; Nuciforo P; Fletcher JA; Arribas J; Politz O; Serrano C
    Mol Cancer Ther; 2020 Jun; 19(6):1289-1297. PubMed ID: 32371592
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictive models for designing potent tyrosine kinase inhibitors in chronic myeloid leukemia for understanding its molecular mechanism of resistance by molecular docking and dynamics simulations.
    Melge AR; Kumar LG; K P; Nair SV; K M; C GM
    J Biomol Struct Dyn; 2019 Nov; 37(18):4747-4766. PubMed ID: 30580670
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interleukin-6 mediates resistance to PI3K-pathway-targeted therapy in lymphoma.
    Kim JH; Kim WS; Park C
    BMC Cancer; 2019 Oct; 19(1):936. PubMed ID: 31601188
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of PI3K by copanlisib exerts potent antitumor effects on Merkel cell carcinoma cell lines and mouse xenografts.
    Fang B; Kannan A; Zhao S; Nguyen QH; Ejadi S; Yamamoto M; Camilo Barreto J; Zhao H; Gao L
    Sci Rep; 2020 Jun; 10(1):8867. PubMed ID: 32483262
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Computational investigation of imidazo[2,1-b]oxazole derivatives as potential mutant BRAF kinase inhibitors: 3D-QSAR, molecular docking, molecular dynamics simulation, and ADMETox studies.
    Boutalaka M; El Bahi S; Alaqarbeh M; El Alaouy MA; Koubi Y; Khatabi KE; Maghat H; Bouachrine M; Lakhlifi T
    J Biomol Struct Dyn; 2024 Jul; 42(10):5268-5287. PubMed ID: 37424193
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacophore derived 3D-QSAR, molecular docking, and simulation studies of quinoxaline derivatives as ALR2 inhibitors.
    Singh Y; Kumar N; Kulkarni S; Singh S; Thareja S
    J Biomol Struct Dyn; 2024; 42(19):10452-10488. PubMed ID: 37698364
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chemical analogue based drug design for cancer treatment targeting PI3K: integrating machine learning and molecular modeling.
    Bazuhair MA; Alghamdi AA; Baothman O; Afzal M; Alzarea SI; Imam F; Moglad E; Altayb HN
    Mol Divers; 2024 Aug; 28(4):2345-2364. PubMed ID: 39154146
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Developing new PI3Kγ inhibitors by combining pharmacophore modeling, molecular dynamic simulation, molecular docking, fragment-based drug design, and virtual screening.
    Zhu J; Sun D; Li X; Jia L; Cai Y; Chen Y; Jin J; Yu L
    Comput Biol Chem; 2023 Jun; 104():107879. PubMed ID: 37182359
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.